189 related articles for article (PubMed ID: 23500098)
1. A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Martin HL; Mounsey RB; Sathe K; Mustafa S; Nelson MC; Evans RM; Teismann P
Neuroscience; 2013 Jun; 240():191-203. PubMed ID: 23500098
[TBL] [Abstract][Full Text] [Related]
2. The effect of neuronal conditional knock-out of peroxisome proliferator-activated receptors in the MPTP mouse model of Parkinson's disease.
Mounsey RB; Martin HL; Nelson MC; Evans RM; Teismann P
Neuroscience; 2015 Aug; 300():576-84. PubMed ID: 26028469
[TBL] [Abstract][Full Text] [Related]
3. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.
Iwashita A; Muramatsu Y; Yamazaki T; Muramoto M; Kita Y; Yamazaki S; Mihara K; Moriguchi A; Matsuoka N
J Pharmacol Exp Ther; 2007 Mar; 320(3):1087-96. PubMed ID: 17167170
[TBL] [Abstract][Full Text] [Related]
5. Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
Kato H; Araki T; Imai Y; Takahashi A; Itoyama Y
J Neurol Sci; 2003 Apr; 208(1-2):9-15. PubMed ID: 12639719
[TBL] [Abstract][Full Text] [Related]
6. Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T
Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
[TBL] [Abstract][Full Text] [Related]
8. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
Teismann P; Ferger B
Synapse; 2001 Feb; 39(2):167-74. PubMed ID: 11180504
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.
Lecca D; Nevin DK; Mulas G; Casu MA; Diana A; Rossi D; Sacchetti G; Fayne D; Carta AR
Neuroscience; 2015 Aug; 302():23-35. PubMed ID: 25907448
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
12. Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARα-Dependent Astrocytic GDNF Pathway.
Gottschalk CG; Jana M; Roy A; Patel DR; Pahan K
J Neurosci; 2021 Mar; 41(10):2287-2300. PubMed ID: 33514677
[TBL] [Abstract][Full Text] [Related]
13. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Yokoyama H; Takagi S; Watanabe Y; Kato H; Araki T
J Neural Transm (Vienna); 2008 Jun; 115(6):831-42. PubMed ID: 18235988
[TBL] [Abstract][Full Text] [Related]
14. Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation.
Malm T; Mariani M; Donovan LJ; Neilson L; Landreth GE
J Neuroinflammation; 2015 Jan; 12():7. PubMed ID: 25592770
[TBL] [Abstract][Full Text] [Related]
15. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
[TBL] [Abstract][Full Text] [Related]
16. Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model.
Fujita A; Yamaguchi H; Yamasaki R; Cui Y; Matsuoka Y; Yamada KI; Kira JI
J Neuroinflammation; 2018 Aug; 15(1):227. PubMed ID: 30103794
[TBL] [Abstract][Full Text] [Related]
17. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.
Garrido-Gil P; Joglar B; Rodriguez-Perez AI; Guerra MJ; Labandeira-Garcia JL
J Neuroinflammation; 2012 Feb; 9():38. PubMed ID: 22356806
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of MHY908, a PPAR α/γ dual agonist, in a MPTP-induced Parkinson's disease model.
Lee Y; Cho JH; Lee S; Lee W; Chang SC; Chung HY; Moon HR; Lee J
Brain Res; 2019 Feb; 1704():47-58. PubMed ID: 30273550
[TBL] [Abstract][Full Text] [Related]
19. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
[TBL] [Abstract][Full Text] [Related]
20. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Yano R; Yokoyama H; Kuroiwa H; Kato H; Araki T
J Mol Neurosci; 2009 Sep; 39(1-2):211-9. PubMed ID: 19199078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
